Patient characteristics
| Characteristic . | All patients N = 82 . | CMV disease N = 20 . | Preemptive therapy . | |
|---|---|---|---|---|
| Primary N = 24 . | Secondary N = 38 . | |||
| Median age, years (range) | 34.7 (0.3-57.7) | 32.3 (0.3-59.0) | 40.9 (17.9-57.5) | 29.8 (0.5-50.9) |
| Donor type | ||||
| Unrelated | 41 | 8 | 14 | 19 |
| Phenotypically identical family donor | 2 | 1 | 0 | 1 |
| HLA-identical sibling donor | 29 | 7 | 9 | 13 |
| Mismatched family donor | 10 | 4 | 1 | 5 |
| Graft type | ||||
| Bone marrow | 39 | 9 | 5 | 25 |
| Peripheral blood stem cells | 42 | 10 | 19 | 13 |
| Cord blood cells | 1 | 1 | 0 | 0 |
| Acute GVHD | ||||
| Grade 0-I | 44 | 10 | 18 | 16 |
| Grade II-IV | 38 | 10 | 6 | 22 |
| Previous antiviral therapy | ||||
| GCV | 13 | 3 | 0 | 10 |
| Foscarnet | 12 | 3 | 0 | 9 |
| Both GCV and foscarnet | 3 | 2 | 0 | 1* |
| GCV combined with foscarnet | 25 | 6 | 0 | 19* |
| No previous therapy | 30 | 6 | 24 | 0 |
| Characteristic . | All patients N = 82 . | CMV disease N = 20 . | Preemptive therapy . | |
|---|---|---|---|---|
| Primary N = 24 . | Secondary N = 38 . | |||
| Median age, years (range) | 34.7 (0.3-57.7) | 32.3 (0.3-59.0) | 40.9 (17.9-57.5) | 29.8 (0.5-50.9) |
| Donor type | ||||
| Unrelated | 41 | 8 | 14 | 19 |
| Phenotypically identical family donor | 2 | 1 | 0 | 1 |
| HLA-identical sibling donor | 29 | 7 | 9 | 13 |
| Mismatched family donor | 10 | 4 | 1 | 5 |
| Graft type | ||||
| Bone marrow | 39 | 9 | 5 | 25 |
| Peripheral blood stem cells | 42 | 10 | 19 | 13 |
| Cord blood cells | 1 | 1 | 0 | 0 |
| Acute GVHD | ||||
| Grade 0-I | 44 | 10 | 18 | 16 |
| Grade II-IV | 38 | 10 | 6 | 22 |
| Previous antiviral therapy | ||||
| GCV | 13 | 3 | 0 | 10 |
| Foscarnet | 12 | 3 | 0 | 9 |
| Both GCV and foscarnet | 3 | 2 | 0 | 1* |
| GCV combined with foscarnet | 25 | 6 | 0 | 19* |
| No previous therapy | 30 | 6 | 24 | 0 |
CMV indicates cytomegalovirus; GVHD, graft-versus-host disease; GCV, ganciclovir.
One patient received both GCV and foscarnet, first separately and then in combination.